Slide 1: Simulations Plus, Inc. First Quarter FY 2011 Conference Call and Webinar
Simulations Plus, Inc. (NASDAQ:SLP) First Quarter FY 2011 Conference Call and Webinar January 14, 2011
Slide 2: Safe Harbor Statement
With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to such
Slide 3: SLP 1Q11 Highlights
• 1Q11 was another record 1 st quarter: – 13 th consecutive profitable quarter – 1Q11 sales up 15.4% to $2.81 MM from $2.44 MM in 1Q10. – Net Income up 32.0% for the quarter over 1Q10 – Pharmaceutical segment sales up 18.2% over 1Q10 – Words+ subsidiary sales up 8.3% over 1QFY10 • Strong balance she
Slide 4: A on
A on ey $28 $28 $24 A $22 9 | sis | 4008 1009 2Q09 3009 4Q09 1010 2010 3010 4a10 1011 simulations plus, inc. é
Slide 5: Quarterly Revenues Annual Revenues
Quarterly Revenues Annual Revenues a eRe Me MLL, p00 2007 2008 2009 2010 = Pharmaceutical =" Words+ ‘=Pharmaceutical = Words+ simulations plus, inc. é
Slide 6: Quarterly Revenues
Quarterly Revenues ® 2 S 2 oe 1Q08 2Q08 308 4208 1Q09 2Q09 309 4Q09 1A10 2A10 3a10 4a10 1011 simulationsplus, inc. é
Slide 7: Gross Margin (consolidated)
Gross Margin (consolidated) 75.6% 78.9% 78.8% 70.4% 73.8% 74.4% 80.0% 67.9% 75.0% 76.3% 77.6% 75.6% 73.6%
Slide 8: 1008 2008 3Q08 4008 1009 2009 3Q09 4009 2Q10 sQ10 4Q10 11
1008 2008 3Q08 4008 1009 2009 3Q09 4009 110 2Q10 sQ10 4Q10 111 simulations plus, inc. é
Slide 9: Net Income
Net Income $243K $565K $764K $165K $312K $368K $569K $163K $430K $641K $740K $345K $567K
Slide 10: Consolidated Income Statement
1Q11 1Q10 Pharmaceutical software and services revenue 2.050 1.735 Words+ revenue 0.761 0.702 Consolidated revenue 2.811 2.437 Gross profit 2.070 1.830 Gross profit margin 73.6% 75.1% SG&A 1.062 1.004 R&D 0.208 0.261 Total operating expenses 1.270 1.265 Income before income taxes 0.825 0.661 Net inc
Slide 11: Select Balance Sheet Items
November 30, 2010 November 30, 2009 Cash and cash equivalents $8.87 $7.97 Total current assets 11.775 10.750 Total assets $14.063 $12.828 Total current liabilities 1.095 1.227 Total liabilities 1.581 2.017 Shareholders’ equity 12.482 10.812 Total liabilities and shareholders’ equity 14.063 12.828 Se
Slide 12: Share Repurchase Program
Share Repurchase Program • The board of directors approved a second share repurchase program beginning February 2010 for one year (Phase II) • The Phase II program authorizes repurchase of up to 1,000,000 shares through February 2011 • The purpose of the program is to use some of our excess cash to
Slide 13: Aggressive Marketing and Sales Program
Aggressive Marketing and Sales Program • Our development and consulting scientists continue to be actively involved in scientific meetings, with numerous poster and podium presentations and staffing exhibit booths • Fundamental industry shift continues – Pharma increasingly utilizing simulation soft
Slide 14: Simulations Plus continues to increase its technological advantage
• Simulations Plus continues to increase its technological advantage Ongoing Enhancements • Version 7.0 was released in August - a major upgrade • Three new market-expanding capabilities plus numerous features: • Drug-to-drug interaction • Ocular drug delivery • Nasal/pulmonary drug delivery • Versi
Slide 15: WAR EAGLE! Auburn University wins National Championship!
WAR EAGLE! Auburn University wins National Championship!
Slide 16: simulations plus, inc. é
simulations plus, inc. é